Biosite Diagnostics Incorporated has announced the launch of a collaborative Biosite Discovery program to identify novel proteins that can advance care for patients with acute coronary syndrome, or ischemic heart disease, the most common cause of death worldwide.
The collaboration leverages Biosite’s existing partnership with Large Scale Proteomics Corporation and introduces new clinical collaborators, including the Thrombolysis In Myocardial Infarction (TIMI) Study Group, an investigation team that has been at the forefront of clinical research in acute coronary syndromes over the past two decades.
“We urgently need more accurate tests for the diagnosis and risk stratification of acute coronary syndrome in order to improve prospects for the millions of patients who visit emergency departments each year with chest pain of unknown cause,” said Dr. Eugene Braunwald, chairman of the TIMI Trials.
“We hope that this collaboration will speed the development of such tests.”
Under the terms of the collaboration, Biosite Discovery would continue its ongoing evaluation of at least 30 known markers, using its Omniclonal phage display technology to perform research and assay development.
Biosite would analyse markers for diagnostic utility using clinical samples provided by the TIMI Study Group, among others.
Clinical samples would also be provided to Large Scale Proteomics, which would apply its proteomics technology for protein target discovery.
Large Scale Proteomics would conduct further research on promising targets and would also send these to Biosite for diagnostic evaluation.
As part of the agreement, Biosite would provide Large Scale Proteomics with Omniclonal antibody services to aid in their research.
Large Scale Proteomics Corporation is a leading provider of proteomic technologies to the life sciences industry and is located in Rockville, Md. The TIMI Study Group organized in 1984 and led by Dr. Eugene Braunwald of Brigham and Women’s Hospital in Boston, Mass., is committed to advancing the knowledge and care of patients suffering from acute coronary syndromes by performing clinical research.
Biosite Diagnostics Incorporated is dedicated to meeting important clinical needs in emergency medicine by speeding the flow of critical diagnostic information.
Through its integrated discovery and diagnostics businesses, Biosite seeks to develop rapid diagnostic tests that improve clinical and economic outcomes for acute diseases.